Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 9/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042539 | 1.00 | CA2 (0.46) | CA2CHKATRPV4FEN1ALOX5AP | |
| Hydrochloric Acid SCHEMBL31336743 | 0.98 | CA2 (0.45) | CA2CHKATRPV4FEN1ALOX5AP | |
| SCHEMBL27976387 | 0.84 | CA2 (0.36) | CA2CHKATRPV4FEN1ALOX5AP | |
| SCHEMBL14786224 | 0.81 | HSP90AA1 (0.36) | CA2CHKATRPV4FEN1ALOX5AP | |
| SCHEMBL14786313 | 0.81 | HSP90AA1 (0.36) | CA2CHKATRPV4FEN1ALOX5AP | |
| SCHEMBL14683983 | 0.78 | GCK (0.37) | CA2CHKAFEN1ALOX5APHSP90AA1 | |
| SCHEMBL2739648 | 0.75 | NOS3 (0.41) | FEN1ALOX5APHSP90AA1KDM4ENOS3 | |
| SCHEMBL28021874 | 0.75 | KCNH2 (0.50) | TRPV4FEN1ALOX5APPIK3CDPIK3CA | |
| SCHEMBL647114 | 0.74 | — | — | |
| SCHEMBL30224817 | 0.72 | TRPV4 (0.44) | CA2CHKATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | claimed |
| CN-117165078-A | Cyanate resin with low dielectric loss suitable for winding forming process, preparation method and application | 中国科学院宁波材料技术与工程研究所 | 2023-12-05 | — | — | CN | claimed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | claimed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | claimed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4583870-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Mito Biopharma, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025104154-A1 | 5-[2,7-DIAZASPIRO[3.5]NONAN-7-YL]-5-[4-PHENOXYPHENYL]HEXAHYDROPYRIMIDINE-2,4,6-TRIONE DERIVATIVES AS MMP9 INHIBITORS FOR THE TREATMENT OF DRY EYE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| CN-1507436-A | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | — | 2004-06-23 | — | — | CN | disclosed |
| EP-1379510-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
| WO-2002070494-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| US-5079251-A | Insecticides, pesticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-01-07 | — | — | US | disclosed |
| EP-0408196-A2 | Pyrazinone derivatives as insecticides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-01-16 | — | — | EP | disclosed |
| US-4293552-A | Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas | ELI LILLY AND COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4160834-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | CA2 1936/4885CHKA 2207/4885TRPV4 2230/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | CA2 1313/4885CHKA 4559/4885TRPV4 321/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | CA2 1936/4885CHKA 2207/4885TRPV4 2230/4885 |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | CA2 2005/4885CHKA 4704/4885TRPV4 2626/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | CA2 4469/4885CHKA 159/4885TRPV4 4817/4885 |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | SPR, QDPR, SUCNR1 | CA2 2150/4885CHKA 2733/4885TRPV4 190/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | CA2 3351/4885CHKA 1912/4885TRPV4 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.